Teva Pharmaceuticals
TEVA
TEVA
529 hedge funds and large institutions have $9.87B invested in Teva Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 86 funds opening new positions, 189 increasing their positions, 153 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
529
Holders Change
+52
Holders Change %
+10.9%
% of All Funds
7.69%
Holding in Top 10
25
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+4.17%
% of All Funds
0.36%
New
86
Increased
189
Reduced
153
Closed
25
Calls
$577M
Puts
$124M
Net Calls
+$453M
Net Calls Change
+$336M
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
$682M |
| 2 |
Morgan Stanley
New York
|
$214M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
$94.3M |
| 4 |
Invesco
Atlanta,
Georgia
|
$77.2M |
| 5 |
PC
PointState Capital
New York
|
$149M |
Top Sellers
| 1 |
PF
Phoenix Financial
Givatayim,
Israel
|
$413M |
| 2 |
SPC
Slate Path Capital
New York
|
$328M |
| 3 |
Citadel Advisors
Miami,
Florida
|
$28.7M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
$9.53M |
| 5 |
Citigroup
New York
|
$15.2M |
